Table 6 – STI Treatment Guidelines
Recommended doses of licensed formulations of hepatitis B vaccines
|Age group (yrs)||Single-antigen vaccine||Combination vaccine|
|Dose (μg)§||Volume (mL)||Dose (μg)§||Volume (mL)||Dose (μg)§||Volume (mL)||Dose (μg)§||Volume (mL)|
|Hemodialysis patients and other immunocompromised persons (<20§§)||5||0.5||10||0.5||20||0.5||NA||NA|
|Hemodialysis patients and other immunocompromised persons (≥20)||40¶¶||1||40***||2.0||20||0.5||NA||NA|
Source: Adapted from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1).
Abbreviation: NA = not applicable.
* Administered on a 2-dose schedule.
† Combined hepatitis A and B vaccines. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B and hepatitis A virus infections.
§ Recombinant hepatitis B surface antigen protein dose.
¶ Heplisav-B should not be used for vaccination of infants, children, or adolescents because the safety and effectiveness of Heplisav-B has not been established in persons aged <8 years and is not approved for use in these populations.
** Adult formulation administered on a 2-dose schedule.
†† Engerix-B and Recombivax HB are approved for use in persons of all ages.
§§ Higher doses might be more immunogenic; however, no specific recommendations have been made.
¶¶ Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
*** Two 1.0-mL doses administered at one site, on a 4-dose schedule at 0, 1, 2, and 6 months.